Home / News

IFCC-RELA 2022, Snibe reference testing laboratory successfully passed the proficiency testing of 9 projects!

2022/12/7 17:01:43 Views£º414

Snibe reference testing laboratory passed all nine projects (seven in clinical enzymology, one in vitamins and one in hormones) in which it participated in the IFCC-RELA 2022.



IFCC-RELA Address£ºhttp://dgkl-rfb.de:81/

Snibe reference testing laboratory is Laboratory No. 195.

 

RELA for Laboratory Medicine is an inter-laboratory quality assessment activity for medical reference laboratories worldwide, organized by The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and hosted by the German Society of Clinical Chemistry, and has been conducted annually since 2003. It represents the highest level of clinical chemistry and laboratory medicine and is recognized as the highest level of quality evaluation activity in the international field of clinical chemistry and laboratory medicine. Global reference laboratories demonstrate the technical competence of laboratory reference measurements by participating in this inter-room quality evaluation activity and having results that meet the requirements.

 


In order to ensure the accuracy of the results and the traceability of the customer's clinical test results to international/national standards, an uninterrupted traceability chain of "International System of Units (SI) - Reference Laboratory - Clinical Laboratory" is established to ensure the accuracy of the product test results. Finally, the mutual recognition of clinical test results is realized. Snibe established a reference laboratory in 2021, and now has two platforms: UV-Vis spectrophotometer and ultra-high performance liquid chromatography-tandem mass spectrometer, which strongly guarantee the traceability and standardization of Snibe 's products.



CAIVD WeChat
Subscription Account
CAIVD WeChat
Channels

China Association of In-vitro Diagnostics

Part of the information in our website is from the internet.

If by any chance it violates your rights, please contact us.